# A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

> **NCT06698822** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Cutaneous T-Cell Lymphoma

## Interventions

- **DRUG:** tofacitinib 2% cream

## Key facts

- **NCT ID:** NCT06698822
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2026-10-19
- **Final completion:** 2026-10-19
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06698822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06698822, "A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06698822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*